Praxis pauses vormatrigine study after trial misses primary endpoint
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
Raymond James sees a 'unique buying opportunity' in this stock
June 2, 2026 4:00 PM EDTRaymond James believes the recent selloff in one biopharmaceutical companys shares has created an attractive entry point for investors, arguing that disappointment surrounding the company's vormatrigine program does not alter its core investment thesis.
In a research note, Raymond James analyst Tiago Fauth reiterated a Strong Buy rating on Praxis Precision Medicines (NASDAQ: PRAX) and maintained a Strong Buy rating despite a failed... More
